CHA2 DS2 -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation.
Thomas JensenPernille Gro ThraneKevin Kris Warnakula OlesenMorten WürtzJens Cosedis NielsenLisette Okkels JensenMorten MadsenTroels ThimSteen Dalby KristensenGregory Yoke Hong LipMichael MaengPublished in: European journal of clinical investigation (2021)
Implementation of the CHA2 DS2 -VASc score in the 2010 European guidelines on AF was associated with an increased utilization of oral anticoagulation and triple therapy among AF patients undergoing PCI. These changes were associated with a gradual decline in the risk of MACE, while the risk of hospitalized bleeding remained unchanged.
Keyphrases
- atrial fibrillation
- percutaneous coronary intervention
- patients undergoing
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- oral anticoagulants
- catheter ablation
- left atrial
- antiplatelet therapy
- coronary artery bypass grafting
- left atrial appendage
- direct oral anticoagulants
- primary care
- heart failure
- healthcare
- acute coronary syndrome
- coronary artery disease
- clinical practice
- coronary artery bypass
- venous thromboembolism
- stem cells
- replacement therapy